Advertisement

CardioVascular and Interventional Radiology

, Volume 39, Issue 6, pp 885–893 | Cite as

Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients

  • M. Barral
  • A. Auperin
  • A. Hakime
  • V. Cartier
  • V. Tacher
  • Yves Otmezguine
  • L. Tselikas
  • T. de Baere
  • F. Deschamps
Clinical Investigation

Abstract

Objective

To evaluate prognostic factors associated with local control and disease-free-survival (DFS) of oligometastatic breast cancer patients treated by percutaneous thermal ablation (PTA).

Materials and Methods

Seventy-nine consecutive patients (54.5 ± 11.2 years old) with 114 breast cancer metastases (28.9 ± 16.1 mm in diameter), involving the lungs, the liver, and/or the bone, were treated using PTA with a curative intent. The goal was to achieve a complete remission in association with systemic chemotherapy and hormonal therapy. We retrospectively evaluated the prognostic factors associated with 1- and 2-year local control and the 1- and 2-year DFS rates.

Results

The 1- and 2-year local control rates were 83.0 and 76.1 %, respectively. Tumor burden was associated with a poorer outcome for local control after PTA (HR 1.027 by additional millimeter, p = 0.026; >4 cm HR 3.90). The 1- and 2-year DFS rates were 54.2 and 30.4 %, respectively. In multivariate analysis, triple-negative histological subtype and increased size of treated metastases were associated with a poorer DFS (HR 2.22; 95 % CI [1.13–4.36]; p = 0.02 and HR 2.43; 95 % CI [1.22–4.82]; p = 0.011, respectively).

Conclusion

PTA is effective for local control of breast cancer oligometastases. Tumor burden >4 cm and triple-negative histological subtype are associated with a poorer outcome.

Keywords

Breast neoplasms Metastases Radiofrequency ablation Microwave ablation Cryotherapy 

Abbreviations

PTA

Percutaneous thermal ablation

DFS

Disease-free survival

CT

Computed tomography

MRI

Magnetic resonance imaging

FDG-PET

Fluoro-deoxy-glucose positron emission tomography

OS

Overall survival

Notes

Compliance with Ethical Standards

Conflict of Interest

All authors of the manuscript: Barral Matthias, Aupérin Anne, Hakimé Antoine, Cartier Victoire, Tacher Vania, Otmezguine Yves, Tselikas Lambros, de Baere Thierry, and Deschamps Frédéric have nothing to disclose.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

References

  1. 1.
    Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345–89.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;2009:225–49.CrossRefGoogle Scholar
  3. 3.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;12(384):164–72.CrossRefGoogle Scholar
  5. 5.
    Holmes FA, Buzdar AU, Kau S-W, et al. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED)—the M. D. Anderson experience. Breast Dis. 1994;7:7–20.Google Scholar
  6. 6.
    Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist. 2003;8:241–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Bathe OF, Kaklamanos IG, Moffat FL, Boggs J, Franceschi D, Livingstone AS. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surg Oncol. 1999;8:35–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86:336–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;1(83):878–86.CrossRefGoogle Scholar
  11. 11.
    Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology. 2001;220:145–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Lawes D, Chopada A, Gillams A, Lees W, Taylor I. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. Ann R Coll Surg Engl. 2006;88:639–42.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gunabushanam G, Sharma S, Thulkar S, et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol. 2007;18:67–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. Am J Roentgenol. 2007;189:883–9.CrossRefGoogle Scholar
  15. 15.
    Meloni MF, Andreano A, Laeseke PF, Livraghi T, Sironi S, Lee FT. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation intermediate and long-term survival rates. Radiology. 2009;253:861–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Jakobs TF, Hoffmann RT, Schrader A, et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Interv Radiol. 2009;32:38–46.CrossRefGoogle Scholar
  17. 17.
    Palussière J, Dixmerias F, Buy X, et al. Interventional radiology procedures in the treatment of bone metastasis. Cancer. 2009;96:1117–26.Google Scholar
  18. 18.
    Gangi A, Buy X. Interventional radiology in lung cancer: from diagnosis to treatment. Rev Mal Respir. 2007;24(6):137–45.CrossRefGoogle Scholar
  19. 19.
    de Baere T, Palussiere J, Auperin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240:587–96.CrossRefPubMedGoogle Scholar
  20. 20.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.PubMedGoogle Scholar
  21. 21.
    Bergenfeldt M, Jensen BV, Skjoldbye B, Nielsen D. Liver resection and local ablation of breast cancer liver metastases. A systematic review. EJSO. 2011;37:549–57.CrossRefPubMedGoogle Scholar
  22. 22.
    Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the international registry of lung metastases. J Thorac Oncol. 2011;6:1373–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14:28–37.CrossRefGoogle Scholar
  24. 24.
    Singh D, Chen Y, Hare MZ, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis. 2014;6:369–74.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Lermite E, Marzano E, Chéreau E, Rouzier R, Pessaux P. Surgical resection of liver metastases from breast cancer. Surg Oncol. 2010;19:79–84.CrossRefGoogle Scholar
  27. 27.
    Illing R, Gillams A. Radiofrequency ablation in the treatment of breast cancer liver metastases. Clin Oncol. 2010;22:781–4.CrossRefGoogle Scholar
  28. 28.
    Gervais DA. Cryoablation versus radiofrequency ablation for renal tumor ablation: time to reassess? J Vasc Interv Radiol. 2013;24:1135–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Vogl TJ, Farshid P, Naguib NN, et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. Abdom Imaging. 2015;40(1829–1837):35.Google Scholar
  30. 30.
    Gazelle GS, McMahon PM, Beinfeld MT, Halpern EF, Weinstein MC. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiology. 2004;233:729–39.CrossRefPubMedGoogle Scholar
  31. 31.
    Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009;19:1206–13.CrossRefPubMedGoogle Scholar
  32. 32.
    Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Palussiere J, Lagarde P, Aupérin A, Deschamps F, Chomy F, de Baere T. Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer: results of eight years’ experience in 87 patients from two centers. Cardiovasc Intervent Radiol. 2015;38:160–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Iguchi T, Hiraki T, Gobara H, et al. Percutaneous radiofrequency ablation of lung cancer presenting as ground-glass opacity. Cardiovasc Intervent Radiol. 2015;38:409–15.CrossRefPubMedGoogle Scholar
  35. 35.
    Wei Z, Ye X, Yang X, et al. Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. Cardiovasc Intervent Radiol. 2015;38:135–42.CrossRefPubMedGoogle Scholar
  36. 36.
    Koelblinger C, Strauss S, Gillams A. Outcome after radiofrequency ablation of sarcoma lung metastases. Cardiovasc Intervent Radiol. 2014;37:147–53.CrossRefPubMedGoogle Scholar
  37. 37.
    Deschamps F, Farouil G, Ternes N, et al. Thermal ablation techniques: a curative treatment of bone metastases in selected patients? Eur Radiol. 2014;24:1971–80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2016

Authors and Affiliations

  • M. Barral
    • 1
  • A. Auperin
    • 2
  • A. Hakime
    • 1
  • V. Cartier
    • 1
  • V. Tacher
    • 1
  • Yves Otmezguine
    • 3
  • L. Tselikas
    • 1
  • T. de Baere
    • 1
  • F. Deschamps
    • 1
  1. 1.Interventional Radiology DepartmentInstitut Gustave RoussyVillejuifFrance
  2. 2.Biostatistics and Epidemiology UnitInstitut Gustave RoussyVillejuifFrance
  3. 3.RadiotherapyCentre Clinique de la Porte de Saint-CloudBoulogne BillancourtFrance

Personalised recommendations